Phytoestrogens and breast cancer prevention: Possible mechanisms of action

Environmental Health Perspectives

Volumn 116, Issue 4, 2008, Pages 426-433

  Mense, Sarah M ^a   Hei, Tom K ^a   Ganju, Ramesh K ^b   Bhat, Hari K ^a  

^a Columbia University ^*  (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Catechol estrogen; Catechol O methyltransferase; Chemoprevention; Cytochrome P450; Estrogen; Estrogen receptor; Phytoestrogen

Indexed keywords

APIGENIN; AROMATASE; BIOCHANIN A; CHRYSIN; COUMESTROL DERIVATIVE; CYTOCHROME P450; DAIDZEIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLAVONE DERIVATIVE; FLAVONONE DERIVATIVE; GENISTEIN; HESPERETIN; ISOFLAVONE; ISOFLAVONE DERIVATIVE; LIGNAN DERIVATIVE; PHYTOESTROGEN; PLANT MEDICINAL PRODUCT; QUERCETIN; RESVERATROL; STILBENE DERIVATIVE;

APOPTOSIS; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; EMBASE; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN METABOLISM; EVIDENCE BASED MEDICINE; GENETIC RISK; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; MEDLINE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SOYBEAN;

ANIMALS; ANTICARCINOGENIC AGENTS; AROMATASE; BREAST NEOPLASMS; CELL ENLARGEMENT; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; DIET; ESTROGENS; HUMANS; PHYTOESTROGENS; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 45749095829     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.10538     Document Type: Review

References (145)

1. Adlercreutz H. 1998. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab 12(4):605-623.
2. Adlercreutz H. 2002. Phyto-oestrogens and cancer. Lancet Oncol 3(6):364-373.
3. Adlercreutz H, Markkanen H, Watanabe S. 1993. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342(8881):1209-1210.
4. Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, et al. 2004. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis 25(2):211-218.
5. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. 2001. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 61(13):5045-5050.
6. American Cancer Society. 2006. Cancer Statistics 2006. Available: http://www.cancer.org/docroot/PR0/content/ PRO_1_1_Cancer_Statistics_2006_presentation.asp [accessed 11 November 2007]. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Witman DC. 2001. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276(21):1780B-17814.
7. Arai Y, Uehara M, Sato Y, Kimira M, Eboshida A, Adlercreutz H, et al. 2000. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 10(2):127-135.
8. Ashby J, Tinwell H, Pennie W, Brooks AN, Lefevre PA, Beresford N, et al. 1999. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J Appl Toxicol 19(1):39-45.
9. Badawi AF, Cavalieri EL, Rogan EG. 2001. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 50(9):1001-1003.
10. Balabhadrapathruni S, Thomas TJ, Yurkow EJ, Amenta PS. Thomas T. 2000. Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA- MB-468 human breast cancer cells. Oncol Rep 7(1):3-12.
11. Balle P, McCann A, McGoldrick A, McAllister K, Kennedy M. Dervan P, et al. 2004. Estrogen receptor alpha and beta profiling in human breast cancer. Eur J Surg Oncol 30(5): 469-474.
12. Banerjee S, Bueso-Ramos C, Aggarwal BB. 2002. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62(17):4945-4954.
13. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J. Nilsson S. 1998. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54(1):105-112.
14. Berge G, Ovrebo S, Botnen IV, Hewer A, Phillips ON, Haugen A, et al. 2004. Resveratrol inhibits benzo[alpyrene-DNA adduct formation in human bronchial epithelial cells. Br J Cancer 91(2):333-338.
15. Bhat HK Calaf G, Hei TK, Loya T, Vadgama JV. 2003. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci USA 100(7):3913-3918.
16. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. 2001. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61(20):7456-7463.
17. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. 2000. Resveratrol arts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141(10):3657-3667.
18. Brooks JD, Thompson LU. 2005. Mammalian lignans and genistein decrease the activities of aromatase and 17beta- hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 94(5):461-467.
19. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF, Mabry TJ. 2002. Flavonoid effects relevant to cancer. J Nutr 132(suppl 11):3482S-3489S.
20. Casper RF, Ouesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, et al. 1999. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56(4):784-790.
21. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. 2006. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766(1):63-78.
22. Chan HY, Wang H, Leung LK. 2003. The red clover (Trifolium pratense) isoflavone biochanin A modulates the biotransformation pathways of 7,12-dimethylbenz[1]anthracene. Br J Nutr 90(1):87-92.
23. Chang TK, Chen J, Lee WB. 2001. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299(3):874-882.
24. Chen WF, Huang MH, Tzang CH, Yang M, Wong MS. 2003. Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim Biophys Acta 1638(2):187-196.
25. Chen ZH, Hurh YJ, Na HK, Kim JH, Chun YJ, Kim DH, et al. 2004. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and ccultured human estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 25(10):2005-2013.
26. Chun YJ, Kim MY, Guengerich FP. 1999. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262(1):20-24.
27. Ciolino HP, Daschner PJ, Yeh GC. 1999. Diatery flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J 340 (pt 3):715-722.
28. Ciolino HP, Yeh GC. 1999. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56(4):760-767.
29. Constantinou AI, Lantvit D, Hawthorne M, Xu X, van Breemen RB, Pozzuto JM. 2001. Chemopreventive-effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer 41(1-2):75-81.
30. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. 1999. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 84(10):3479-3484.
31. Evans BA, Griffiths K, Morton MS. 1995. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147(2): 295-302.
32. Fritz WA, Coward L, Wang J, Lamartiniere CA. 1998. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis 19(12): 2151-2158.
33. Garvin S, Ollinger K, Dabrosin C. 2006. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231(l):113-122.
34. Gehm BD, McAndrews JM, Chien PY, Jameson JL. 1997. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Aced Sci USA 94(25):14138-14143.
35. Gikas PO, Mokbel K. 2005. Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Womens Med 50(6):250-258.
36. Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar PH. 2003. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22(30):4702-4709.
37. Griffiths LA, Smith GE. 1972. Metabolism of apigenin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem J 128(4):901-911.
38. Gunnarsson C, Ahnstrom M, Kirschner K, Olsson B. Nordenskjold 8, Rutqvist LE, et al. 2003. Amplification of HSD17B1 and ERB82 in primary breast cancer. Oncogene 22(1):34-40.
39. Guo JM, Kang GZ, Xiao BX, Liu DR, Zhang S. 2004. Effect of daidzem on cell growth, cell cycle, and telomerase activity of human cervical cancer in vitro. Int J Gynecol Cancer 14(5):882-888.
40. Hall JM, McDonnell DP. 1999. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140(12):5566-5578.
41. Han EH, Kim JY, Jeong HG. 2006. Effect of biochanin A on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Arch Pharm Res 29(7):570-576.
42. Hargreaves DF, Patten CS, Harding C, Shaw LE, Morton MS, Roberts SA. et al. 1999. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 84(11):4017-4024.
43. Harris DM, Besselink E, Henning SM, Go VL, Haber D. 2005. Phytoestrogens induce differential estrogen receptor alpha- or beta-mediated responses in transfected breast cancer cells. Exp Biol Med (Maywood) 230(8):558-568.
44. Hilakivi-Clarke L, Onojafe I, Raygada M, Cho E, Skaar T, Russo I, et al. 1999. Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer 80(11): 1682-1688.
45. Hirayama T. 1990a. A large scale cohort study on the effect of life styles on the risk of cancer by each site [in Japanese]. Gan No Rinsho Spec No;233-242.
46. Hirayama T. 1990b. Contribution of a long-term prospective cohort study to the issue of nutrition and cancer with special reference to the role of-alcohol drinking. Prog Clin Biol Res 346:179-187.
47. Hirohata T, Shigematsu T, Nomura AM, Nomura Y, Horie A, Hirohata, I. 1985. Occurrence of breast cancer in relation to diet and reproductive history: a case-control study in Fukuoka, Japan. Natl Cancer Inst Monogr 69:187-190.
48. Hirose K, Tajima K, Hamajima N. Inoue M, Takezaki T, Kuroishi T, et al. 1995. A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 86(2):146-154.
49. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. 1998. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cencar (MCF-7) cells in vivo and in vivo. Cancer Res 58(17)3833-3838.
50. IARC (International Agency for Research on Cancer). 1987. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl 7:272-310
51. IARC (International Agency for Research on Cancer). 1999. Hormonal contraception and postmenopausal hormone therapy. IARC Monogr Eval Carcinog Risks Hum 72:474-530.
52. Ilse R, Han D, Takahashi Y, Terasaka S, Inoue A, Tanji M, et al. 2005. Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray. FEBS Lett 579(7):1732-1740.
53. Jeong HJ, Shin YG, Kim IH, Pezzuto JM. 1999. Inhibition of aromatase activity by flavonoids. Arch Pharm Res 22(3):309-312.
54. Jin Z, MacDonald RS. 2002. Soy isoflavones increase latency of spontaneous mammary tumors in mice. J Nutr 132(10): 3186-3190.
55. Ju YH, Allred KF, Allred CO, Helferich WG. 2006a. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 27(6):1292-1299.
56. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG. 2006b. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 27(4):856-863.
57. Key TJ, Sharp GB, Appleby PN, Beral V, Goodman MT, Soda M, et al. 1999. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 81(7):1248-1256.
58. Kijkuokool P, Parhar IS, Malaivijitnond S. 2006. Genistein enhances N-nitrosomethylurea-induced rat mammary tumorigenesis. Cancer Lett 242(l):53-59.
59. Koehler KF. Helguero LA, Haldosen LA, Warner M, Gustafsson JA. 2005. Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26(3):465-478.
60. Kostelac D, Rechkemmer G, Briviba K. 2003. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J Agric Food Chem 51(26):7632-7635.
61. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138(3):863-870.
62. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139(10):4252-4263.
63. Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE. 2002. The specific role of isoflavones on estrogen metabolism in pre-menopausal women. Cancer 94(4):1166-1174.
64. Kandu JK, Surh YJ. 2004. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 555(1-2):65-80.
65. Lamartiniere CA. 2000. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 71(suppl 6): 1705S-1707S; discussion 1708S-1709S.
66. Lamartiniere CA, Zhang JX, Cotronoo MS. 1998. Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr 68(suppl 6):1400S-1405S.
67. Le Bail JC, Champavier Y, Chulia AJ, Habrioux G. 2000. Effects of phytoestrogens on aromatose, 3beta and 17beta-hydroxy-steroid dehydrogenase activities and human breastcancer cells. Life Sci 66(14):1281-1291.
68. Le Bail JC, Laroche T, Marre-Fournier F, Habrioux G. 1998. Aromatose and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett 133(1):101-106.
69. Lee JE, Safe S. 2001. Involvement al a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cAcer cells. Biochem Pharmacol 62(8):1113-1124.
70. Lehmann L, Esch HL, Wagner J, Rohnstock L, Metzler M. 2005. Estrogenic and genotoxic potential of equol and two hydroxylated metabolites of daidzein in cultured human Ishikawa cells. Toxicol Lett 158(1):72-86.
71. Levin ER. 1999. Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol Metab 10(9):374-377.
72. Li KX, Smith RE, Krozowski ZS. 1998. Cloning and expression of a novel tissue specific l7beta-hydroxysteroid dehydrogenase. Endocr Res 24(3-4):663-667.
73. Li Y, Sarkar FH. 2002. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signalling pathway. Clin Cancer Res 8(7):2369-2377.
74. Liu J, Knappenberger KS, Kack H, Andersson G, Nilsson E, Dartsch C, et al. 2003. A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. Mol Endocrinol 17(3):346-355.
75. Lu LJ, Anderson KE, Grady JJ, Kahan F, Nagamaki M. 2000a. Decreased ovarian hormones during a soya diet implications for breast cancer prevention. Cancer Res 60(15):4112-4121.
76. Lu LJ, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. 2000b. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 60(5):1299-1305.
77. Lu R, Serrero G. 1999. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179(3):297-304.
78. Maggiolini M, Bonotiglio O, Marsico S, Panno ML, Conni B, Picard D, et al. 2001. Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol 60(3):595-602.
79. 3)H]luteolin. Steroids 66(9):707-719.
80. Marquez DC, Pietras RJ. 2001. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20(39):5420-5430.
81. Maskarinec G, Williams AE, Inouye JS, Stanczyk FZ, Franke AA. 2002. A randomized isoflavone intervention among premenopausal women. Cancer Epidemiol Biomarkers Prev 11(2):195-201.
82. McCarty MF. 2006. Isoflavones made simple-genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66(6):1093-1114.
83. McDonnell DP. 2004. The molecular determinants of estrogen receptor pharmacology. Maturitas 48(suppl l):S7-S12.
84. Messina M, McCaskill-Stevens W, Lampe JW. 2006. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 98(18): 1275-1284.
85. Moon YJ, Wang X, Morris ME. 2006. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20(2):187-210.
86. Morito K, Hirose T, Kinjo J, Hirakawa T, Okawa M. Nohara T, et al. 2001. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 24(4):351-356.
87. Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA. 2002. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 132(10): 168-3171.
88. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. 2004. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 80(1):14-25.
89. Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S, Lamartiniere CA. 1996. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 17(7):1451-1457.
90. Myllymaki S, Haavisto T, Vainio M, Toppari J, Paranko J. 2005. In vitro effects of diethylstilbestrol, genistein, 4-tert-butylphenol, and 4-tert-octylphenol on steroidoganic activity of isolated immature rat ovarian follicles. Toxicol Appl Pharmacol 204(1):69-80.
91. Naciff JM, Jump ML, Torontali SM, Carr GJ, Tiesman JP, Overmann GJ, et al. 2002. Gene expression profile induced by 17alpha-athynyl estradiol, bisphonol A, and genistain in the developing female reproductive system of the rat. Toxicol Sci 68(1):184-199.
92. Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. 1998. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst 90(23):1830-1835.
93. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. 2000. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 59(1):65-85.
94. Nichenametia SN, Taruscio TG, Barney DL Exon JH. 2006. A review of the effects and mechanisms of polyphenolics in cancer. Crit Rev Food Sci Nutr 46(2):161-183.
95. Nomura A, Henderson BE, Lee J. 1978. Breast cancer and diet among the Japanese in Hawaii. Am J Clin Nutr 31(11): 2020-2025.
96. Nomura AM, Hirohata T, Kolonel LN, Hankin JH, Lee J, Stammermann G. 1985. Breast cancer in Caucasian and Japanese womin in Hawaii. Natl Cancer Inst Monogi 69:191-196.
97. NTP. 2002. 10th Report on Carcinogens. Research Triangle Park, NC:National Toxicology Program.
98. Omoto Y, Eguchi H, Yamamoto Yamaguchi Y, Hayashi S. 2003. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer call line MCF7. Oncogene 22(32):5011-5020.
99. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, et al. 1996. Concentrations of astrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81(4):1460-1464.
100. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. 2003. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat 77(2):171-183.
101. Pietras RJ, Levin ER, Szego CM. 2005a. Estrogen receptors and cell signaling [Letter]. Science 310(5745):51-53: author reply 51-53.
102. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. 2005b. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer calls. Steroids 70(5-7):372-381.
103. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM. 2002. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast- cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 64(9):1375-1386.
104. Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A, et al. 2005. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 115(1):74-84.
105. Probst-Hensch NM, Pike MC, McKean-Cowdin R, Stanczyk FZ, Kolonel LN. Henderson BE. 2000. Ethnic differences in post-menopausal plasma oestrogen levels: high oestrone levels in Japanese-American women despite low weight. Br J Cancer 82(11):1867-1870.
106. Ramadass P, Meerarani P, Toborek M, Robertson LW, Hennig B. 2003. Dietary flavonoids modulate PCB-induced oxidative stress, CYP1A1 induction, and AhR-DNA binding activity in vascular endothelial cells. Toxicol Sci 76(1):212-219.
107. Rice S, Mason HD, Whitehead SA. 2006. Phytoestrogans and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosa-luteal cells. J Steroid Biochem Mol Biol 101(4-5):216-225.
108. Rice S, Whitehead SA. 2006. Phytoestrogens and breast cancer - promoters or protectors? Endocr Relat Cancer 13(4):995-1015.
109. Roberts DW, Doerge DR, Churchwell MI, Gamboa da Costa G, Marques MM, Tolleson WH. 2004. Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pretense (red clover). J Agric Food Chem 52(21):6623-6632
110. Routledge EJ, White R, Parker MG, Sumpter JP. 2000. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J Biol Chem 275(46):35986-35993.
111. Sanderson JT, Hordijk J, Denison MS, Springsteel MF, Nantz MR, van den Berg M. 2004. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci 82(1):70-79.
112. Sato M, Pei RJ, Yuri T, Danbara N, Nakane Y, Tsubura A. 2003. Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett 202(2):137-145.
113. Schmitt E. Lehmann L. Metzler M, Stopper H. 2002. Hormonal and genotoxic activity of resveratrol. Toxicol Lett 136(2):133-142
114. Seo HS, Denardo DG, Jacquot Y, Laios I, Vidal DS, Zambrana CR, et al. 2006. Stimulatory effect of genistein and apigenin on the growth of breast cancer calls correlates with their ability to activate ER alpha. Breast Cancer Res Treat 99(2):121-134.
115. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, et al. 2003. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27(12):1502-1512.
116. Shao ZM, Wu J, Shen ZZ, Barsky SH. 1998. Genistain exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58(21):4851-4857.
117. Shertzer HG, Puga A, Chang C, Smith P, Nebert DW, Setchell KD, et al. 1999. Inhibition of CYP1A1 enzyme activity in mouse hepatoma cell culture by soybean isoflavones. Chem Biol Interact 123(1):31-49.
118. 3)H]estradiol binding sites as histone H4. Biochem Biophys Res Commun 296(5):1083-1090.
119. Shoulars K, Rodrigues MA, Crowley JR, Turk J, Thompson T, Markaverich BM. 2005. Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex. J Steroid Biochem Mol Biol 96(1):19-30.
120. Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, et al. 2001. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 10(5):483-488.
121. Sirtori CR, Arnoldi A, Johnson SK. 2005. Phytoestrogens: end of a tale? Ann Med 37(6):423-438.
122. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. 2004. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101(6):1566-1571.
123. Thompson EA, Jr., Siiteri PK. 1974. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of and rostenedione. J Biol Chem 249(17):5364-5372.
124. Trock BJ, Hilakivi-Clarke L, Clarke R. 20D6. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98(7):459-471.
125. Uehar M, Arai Y, Watanabe S, Adlercreutz H. 2000. Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors 12(1-4):217-225.
126. Ursin G, Bernstein L, Pike MC. 1994. Breast cancer. Cancer Surv 19-20:241-264.
127. Usui T. 2006. Pharmaceutical prospects of phytoestrogens. Endocr J 53(1):7-20.
128. Vanden Berghe W, Dijsselbloem N, Vermoulen L, Ndlovu N, Boone E, Haegeman G. 2006. Attenuation of mitogen-and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 66(9):4852-4862.
129. van der Woude H, Ter Veld MG, Jacobs N, van der Saag PT, Murk AJ, Rietjens IM. 2005. The stimulation of cell proliferation by quercetin is mediated by the estrogen receptor. Mol Nutr Food Res 49(8):763-771.
130. Verma AK, Johnson A Gould MN, Tanner MA. 1988. Inhibition of 7,12-dimethylbenz(a)anthracene- and N-nitrosomethyl-urea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res 48(20):5754-5758.
131. Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, et al. 1999. Dietary intake and sources of isoflavones among Japanese. Nutr Cancer 33(2):139-145.
132. Wang Y, Lee KW, Chan FL, Chen S, Leung LK. 2006. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol Sci 92(1):71-77.
133. Whitahead SA, Cross JE, Burden C, Lacey M. 2002. Acute and chronic effects of genistein, tyrphostin and lavendustin A on steroid synthesis in luteinized human granulosa cells. Hum Reprod 17(3):589-594.
134. Whitsett T, Carpenter M, Lamartiniere CA. 2006. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 5:15-26.
135. Wood CE, Register TC, Cline JM.. 2007. Soy isoflavonoid effects on endogenous estrogen metabolism in postmenopausal female monkeys. Carcinogenesis 28(4):801-808.
136. Wu AH, Ziegler RG, Horn-Ross PL, Nomura AM, West DW, Kolonel LN, et al. 1996. Tofu and risk of breast cancer in Asian Americans. Cancer Epidemiol Biomarkers Prev 5(11):901-906.
137. Xu X, Duncan AM, Merz BE, Kurzer MS. 1998. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev 7(12):1101-1108.
138. Yager JD, Davidson NE. 2006. Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270-282
139. Yu R, Hebbar V, Kim DW, Mandlekar S, Pezzuto JM, Kong AN. 2001. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol 60(1):217-224.
140. Yuan JM, Wang QS, Ross RK, Henderson BE, Yu MC. 1995. Diet and breast cancer in Shanghai and Tianjin, China. Br J Cancer 71(6):1353-1358.
141. Yue W, Berstein LM, Wang JP, Clark GM, Hamilton CJ, Demers LM, et al. 2001. The potential role of estrogen in aromatese regulation in the breast. J Steroid Biochem Mol Biol 79(1-5):157-164.
142. Zhu BT. 2002. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 3(3):321-349.
143. Zhu BT, Liehr JG. 1994. Quercetin increases the severity of estradiol-induced tumorigenesis in hamster kidney. Toxicol Appl Pharmacol 125(1):149-158.
144. Zhu BT, Liehr JG. 1996. Inhibition of catechol O-methyltrans ferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis. J Biol Chem 271(3):1357-1363.
145. Ziegler RG. 2004. Phytoestrogens and breast cancer. Am J Clin Nutr 79(2):183-184.